HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia
December 13, 2021 16:30 ET
|
Aptose Biosciences, Inc.
HM43239 Data Featured in Oral Presentation at the American Society of Hematology Annual Meeting Aptose Presents Highlights from Luxeptinib and APTO-253 and Provides Corporate Update SAN DIEGO,...
Aptose to Hold Corporate Update Monday, December 13th
November 29, 2021 07:30 ET
|
Aptose Biosciences, Inc.
HM43239 clinical update in AML after oral presentation at 2021 ASH Annual MeetingLuxeptinib clinical update in AML and B-cell cancers SAN DIEGO and TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Aptose...
Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference
November 22, 2021 16:02 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Reports Results for the Third Quarter 2021
November 11, 2021 16:01 ET
|
Aptose Biosciences, Inc.
- Conference call and webcast at 5:00 pm ET today - - HM43239, myeloid kinome inhibitor with clinically validated activity added to pipeline - - HM43239 phase 1/2 study in AML advances to 200...
Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting
November 04, 2021 09:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239
November 04, 2021 06:00 ET
|
Aptose Biosciences, Inc.
HM43239 delivers multiple complete responses (CRs) in diverse R/R AML patients Aptose to host conference call and webcast today at 9:00 am ET SAN DIEGO and TORONTO and SEOUL, South Korea, Nov. 04,...
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021
October 26, 2021 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose Expands Senior Leadership Team
October 25, 2021 08:00 ET
|
Aptose Biosciences, Inc.
Janet Clennett, CPA, appointed Vice President, Finance Roger Davies, B.Sc., M. Phil, joins as Vice President, Operations SAN DIEGO and TORONTO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences...
Aptose to Present at September Investor Conferences
August 30, 2021 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Reports Results for the Second Quarter 2021
August 03, 2021 16:01 ET
|
Aptose Biosciences, Inc.
- Conference call and webcast at 5:00 pm EDT today - - Luxeptinib Phase 1a/b studies in AML and B cell malignancies fully enrolled at 750 mg dose - - APTO-253 Phase 1a/b study in AML / MDS treating...